Overview
Amyl Therapeutics develops Pan-Amyloid Immunotherapy, described as a groundbreaking approach designed to become a universal treatment for neurodegenerative diseases like Alzheimer's and Parkinson's. The therapy is designed to target toxic amyloid species and act at every stage of disease progression.
Funding & milestones
1 events found for Amyl Therapeutics · 2026
Series AVenture / equity1 source$9.08M
Reported amount $9,075,000
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
Key people
In the news
- Alzheimer's disease involves several toxic protein aggregates, such as amyloid beta, tau and often alpha-synuclein. But most therapies target only one, and very little of a drug reaches the brain. In a new interview with Drug Delivery Leader, our CEO Pierre Vandepapelière explains how Amyl Therapeutics tackles both challenges. A single molecule targets multiple amyloid fibrils, and a safer brain shuttle carries it across the blood-brain barrier. He also shares why early intervention could change everything🧠 👉 You can read the
- Busy weeks ahead for the Amyl Tx team! Our 𝗥&𝗗 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿 Julie Goemaere and our 𝗥&𝗗 Associate Dafni Birmpili will be on stage at three events this autumn: 📍 Growth Across Borders 2026, Legia Park, October 8 Julie Goemaere will be taking part in the event. https://luma.com/1jc7r5y7 📍 Liège Creative, October 23 Dafni Birmpili will present Amyl Tx's therapeutic innovation in Alzheimer's disease at the conference forum. https://lnkd.in/eGMFiNT6 📍 Health Innovation Nexus by BioValley, Strasbourg, November 6 Julie Goemaere
- Amyl Therapeutics in L'Echo! On September 1st, L'Echo published an article featuring Amyl Therapeutics and our CEO, Pierre Vandepapelière, showcasing how our recent €8 million financing is accelerating the advancement of our Alzheimer's disease program toward key upcoming milestones.🧠 This Series A extension, backed equally by public grants and private investors, allows us to: 🔬 Validate the Amyl platform 🚀 Move our candidate toward clinical trials 🤝 Continue our growth in Liège A huge thank you to our investors,
- Amyl Therapeutics secures €8.25M Series A extension to validate novel neurodegenerative disease platform. https://lnkd.in/efBag4AC
- Les Liégeois d'Amyl Therapeutics bouclent une série A de 8,25M€ avec l'aide de Noshaq en vue de développer sa nouvelle plateforme pour lutter contre les maladies neurodégénératives, dont Alzheimer et Parkinson 💊🧠 Dans la foulée, la société devrait agrandir ses laboratoires installés au LégiaPark. Bravo à Pierre Vandepapelière et à toute son équipe 🔬👨🔬#provocateursdepossibles Lire l'article complet dans 📰 L'Echo : Olivier Gosset 📝 Valentin Bianchi 📷 Hans Lucas : https://lnkd.in/eZubBDce
- We're #hiring a new Laboratory and Analytical Operations Lead in Liège, Walloon Region. Apply today or share this post with your network.
- We're #hiring a new Laboratory and Analytical Operations lead in Liège, Walloon Region. Apply today or share this post with your network.
- Job alert ! Amyl Therapeutics is hiring a Lab and Analytical Operations Lead. Do not hesitate to share !
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.